article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

article thumbnail

How does your company’s benchmarking performance stack up against the leading precision health companies in the ecosystem?

Frost & Sullivan

Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem. Small- to mid-sized pharma/biotech players in APAC are rivaling Europe in clinical trials through multiple CRO partnerships in the region, tapping into a population-rich landscape.

article thumbnail

Emmes Applauded by Frost & Sullivan for Streamlining Clinical Trials and for Its Competitive Strategies

Frost & Sullivan

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. SAN ANTONIO, TX.